GenMark Diagnostics Schedules Fourth Quarter and Full Year 2012 Financial Results and Conference Call for March 12, 2013
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its fourth quarter and full year 2012 earnings results after
market close on Tuesday, March 12, 2013. Management will hold a
conference call to review the Company's fourth quarter and full year
2012 performance starting at 4:30 p.m. (Eastern Time) on the same day.
The conference call will be concurrently webcast. The link to the
webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com
under the investor relations section and will be archived for future
reference.
To listen to the conference call, please dial (877) 312-5847 (US/Canada)
or (253) 237-1154 (International) and use the conference ID number
"16992443" approximately five minutes prior to the start time.
About GenMark Diagnostics
GenMark Diagnostics is a leading provider of automated, multiplex
molecular diagnostic testing systems that detect and measure DNA and RNA
targets to diagnose disease and optimize patient treatment. Utilizing
GenMark's proprietary eSensor® detection technology, GenMark's eSensor
XT-8™ system is designed to support a broad range of molecular
diagnostic tests with a compact, easy-to-use workstation and
self-contained, disposable test cartridges. GenMark currently markets
four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping
Test, Respiratory Viral Panel, Thrombophilia Risk Test, and Warfarin
Sensitivity Test. A number of other tests, including HCV Genotyping,
2C19 Genotyping, and 3A4/3A5 Genotyping are in development. For more
information, visit www.genmarkdx.com.
